Human leukocyte immunoglobulin-like receptors in health and disease
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling domains (D). With the exception of the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282874/full |
| _version_ | 1797629009226366976 |
|---|---|
| author | Silvia Redondo-García Christopher Barritt Christopher Barritt Christopher Barritt Charys Papagregoriou Muchaala Yeboah Björn Frendeus Björn Frendeus Mark S. Cragg Mark S. Cragg Ali Roghanian Ali Roghanian |
| author_facet | Silvia Redondo-García Christopher Barritt Christopher Barritt Christopher Barritt Charys Papagregoriou Muchaala Yeboah Björn Frendeus Björn Frendeus Mark S. Cragg Mark S. Cragg Ali Roghanian Ali Roghanian |
| author_sort | Silvia Redondo-García |
| collection | DOAJ |
| description | Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling domains (D). With the exception of the soluble LILRA3, LILRAs mediate immune activation, while LILRB1-5 primarily inhibit immune responses and mediate tolerance. Abnormal expression and function of LILRs is associated with a range of pathologies, including immune insufficiency (infection and malignancy) and overt immune responses (autoimmunity and alloresponses), suggesting LILRs may be excellent candidates for targeted immunotherapies. This review will discuss the biology and clinical relevance of this extensive family of immune receptors and will summarise the recent developments in targeting LILRs in disease settings, such as cancer, with an update on the clinical trials investigating the therapeutic targeting of these receptors. |
| first_indexed | 2024-03-11T10:47:21Z |
| format | Article |
| id | doaj.art-b2d939679c3440e4a96adf5e239476b6 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T10:47:21Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b2d939679c3440e4a96adf5e239476b62023-11-14T02:13:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-11-011410.3389/fimmu.2023.12828741282874Human leukocyte immunoglobulin-like receptors in health and diseaseSilvia Redondo-García0Christopher Barritt1Christopher Barritt2Christopher Barritt3Charys Papagregoriou4Muchaala Yeboah5Björn Frendeus6Björn Frendeus7Mark S. Cragg8Mark S. Cragg9Ali Roghanian10Ali Roghanian11Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomLister Department of General Surgery, Glasgow Royal Infirmary, Glasgow, United KingdomSchool of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, United KingdomAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomBioInvent International AB, Lund, SwedenAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomInstitute for Life Sciences, University of Southampton, Southampton, United KingdomAntibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United KingdomInstitute for Life Sciences, University of Southampton, Southampton, United KingdomHuman leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling domains (D). With the exception of the soluble LILRA3, LILRAs mediate immune activation, while LILRB1-5 primarily inhibit immune responses and mediate tolerance. Abnormal expression and function of LILRs is associated with a range of pathologies, including immune insufficiency (infection and malignancy) and overt immune responses (autoimmunity and alloresponses), suggesting LILRs may be excellent candidates for targeted immunotherapies. This review will discuss the biology and clinical relevance of this extensive family of immune receptors and will summarise the recent developments in targeting LILRs in disease settings, such as cancer, with an update on the clinical trials investigating the therapeutic targeting of these receptors.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282874/fullLILRimmune tolerancecancerautoimmunityinfectionimmunomodulation |
| spellingShingle | Silvia Redondo-García Christopher Barritt Christopher Barritt Christopher Barritt Charys Papagregoriou Muchaala Yeboah Björn Frendeus Björn Frendeus Mark S. Cragg Mark S. Cragg Ali Roghanian Ali Roghanian Human leukocyte immunoglobulin-like receptors in health and disease Frontiers in Immunology LILR immune tolerance cancer autoimmunity infection immunomodulation |
| title | Human leukocyte immunoglobulin-like receptors in health and disease |
| title_full | Human leukocyte immunoglobulin-like receptors in health and disease |
| title_fullStr | Human leukocyte immunoglobulin-like receptors in health and disease |
| title_full_unstemmed | Human leukocyte immunoglobulin-like receptors in health and disease |
| title_short | Human leukocyte immunoglobulin-like receptors in health and disease |
| title_sort | human leukocyte immunoglobulin like receptors in health and disease |
| topic | LILR immune tolerance cancer autoimmunity infection immunomodulation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282874/full |
| work_keys_str_mv | AT silviaredondogarcia humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT christopherbarritt humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT christopherbarritt humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT christopherbarritt humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT charyspapagregoriou humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT muchaalayeboah humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT bjornfrendeus humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT bjornfrendeus humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT markscragg humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT markscragg humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT aliroghanian humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease AT aliroghanian humanleukocyteimmunoglobulinlikereceptorsinhealthanddisease |